A randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of neramexane in patients with moderate to severe subjective tinnitus.

BMC Ear Nose Throat Disord · 2011 · PMC3031239 · PMID 21223542

Europe PMC DOI

hedged sentences

0.0980

closest p · 2.0× alpha

0.0980

boldest claim

The sentences

did not reach statistical significancep = 0.098so close (0.05 < p ≤ 0.1)

This treatment difference did not reach statistical significance at the pre-defined endpoint in Week 16 ( p = 0.098 for 50 mg/d; p = 0.289 for 75 mg/d neramexane), but consistent numerical superiority of both neramexane groups compared with placebo was observed.

also in 111,027 other papers

showed a trendno p-value reported

The primary efficacy variable showed a trend towards improvement of tinnitus suffering in the medium- and high-dose neramexane groups.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.